Loxo Oncology, Inc. (NASDAQ:LOXO) Rating Reiterated by Ifs Securities
Loxo Oncology, Inc. (NASDAQ:LOXO)‘s stock had its “outperform” rating reissued by analysts at Ifs Securities in a report issued on Tuesday.
Other analysts also recently issued research reports about the stock. BTIG Research reissued a “buy” rating and issued a $75.00 price objective on shares of Loxo Oncology in a report on Tuesday, June 6th. Stifel Nicolaus reissued a “buy” rating and issued a $71.00 price objective on shares of Loxo Oncology in a report on Thursday, August 3rd. Zacks Investment Research raised shares of Loxo Oncology from a “hold” rating to a “buy” rating and set a $52.00 price objective for the company in a report on Wednesday, May 3rd. Citigroup Inc. raised shares of Loxo Oncology from a “neutral” rating to a “buy” rating and set a $86.00 price objective for the company in a report on Monday, June 5th. Finally, BidaskClub downgraded shares of Loxo Oncology from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. Loxo Oncology has a consensus rating of “Buy” and an average price target of $79.67.
Loxo Oncology (NASDAQ:LOXO) opened at 72.44 on Tuesday. The company’s market cap is $2.16 billion. Loxo Oncology has a 52 week low of $17.14 and a 52 week high of $83.12. The firm’s 50-day moving average is $75.32 and its 200-day moving average is $54.56.
Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.99) by $0.15. During the same quarter last year, the business posted ($0.77) EPS. On average, analysts expect that Loxo Oncology will post ($4.34) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/11/loxo-oncology-inc-nasdaqloxo-rating-reiterated-by-ifs-securities.html.
In other Loxo Oncology news, Director Keith T. Flaherty sold 7,250 shares of the business’s stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $45.09, for a total value of $326,902.50. Following the completion of the sale, the director now owns 27,141 shares of the company’s stock, valued at approximately $1,223,787.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 44.40% of the company’s stock.
Hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Loxo Oncology by 20.6% in the second quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock worth $128,534,000 after buying an additional 273,291 shares during the period. Emory University purchased a new stake in shares of Loxo Oncology during the second quarter worth $2,738,000. Nationwide Fund Advisors increased its stake in shares of Loxo Oncology by 38.0% in the second quarter. Nationwide Fund Advisors now owns 37,849 shares of the biopharmaceutical company’s stock worth $3,035,000 after buying an additional 10,415 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Loxo Oncology by 316.1% in the second quarter. Ameriprise Financial Inc. now owns 135,776 shares of the biopharmaceutical company’s stock worth $10,887,000 after buying an additional 103,142 shares during the period. Finally, TIAA CREF Investment Management LLC increased its stake in shares of Loxo Oncology by 34.9% in the second quarter. TIAA CREF Investment Management LLC now owns 54,986 shares of the biopharmaceutical company’s stock worth $4,409,000 after buying an additional 14,214 shares during the period.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.